Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab

Clinical and Experimental Rheumatology

Volumn 33, Issue 5, 2015, Pages 655-663

  de Padilla, Consuelo M López ^a   Crowson, Cynthia S ^a,b   Hein, Molly S ^a   Strausbauch, Michael A ^a   Aggarwal, Rohit ^c   Levesque, Marc C ^c   Ascherman, Dana P ^d   Oddis, Chester V ^c   Reed, Ann M ^e  

^a MAYO CLINIC   (United States)

^b Mayo Clinic College of Medicine   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MIAMI   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Core set measures; Refractory inflammatory myopathies; Rituximab; Serum cytokine scores; Toll like receptors

Indexed keywords

GAMMA INTERFERON; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RITUXIMAB; TOLL LIKE RECEPTOR 3; ALPHA INTERFERON; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; CHEMOKINE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MYOSITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VISUAL ANALOG SCALE; BLOOD; CELL CULTURE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PREDICTIVE VALUE; REGULATORY T LYMPHOCYTE; REMISSION; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; BIOMARKERS; CELLS, CULTURED; CHEMOKINES; FEMALE; HUMANS; INTERFERON-ALPHA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYOSITIS; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; RITUXIMAB; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84944398857     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. MILLER F: New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012; 71 (Suppl. 2): i82-5.
2. ERNSTE FC, REED AM: Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc 2013; 88: 83-105.
3. LEVINE T: Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 601-7.
4. CHUNG L, GENOVESE M, FIORENTINO D: A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 2007; 143: 763-7.
5. MAHLER E, BLOM M, VOERMANS N, van ENGELEN, BG, van RIEL, PL, VONK, MC: Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011; 50: 2206-13.
6. ODDIS C, REED A, AGGARWAL R et al.: Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phasetrial. Arthritis Rheum 2013; 65: 314-24.
7. CHINOY H, SALWAY F, JOHN S et al.: Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis 2007; 66: 970-3.
8. TOURNADRE A, LENIEF V, MIOSSEC P: Expression of Toll-like receptor 3 and Tolllike receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum 2010; 62: 2144-51.
9. SHEN H, XIA L, LU J, XIAO W: Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 2011; 403: 217-20.
10. REED A, PETERSON E, BILGIC H et al.: Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 2012; 64: 4078-86.
11. KRIEG AM, VOLLMER J: Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev 2007; 220: 251-69.
12. SCHREINER B, VOSS J, WISCHHUSEN J et al.: Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. FASEB J 2006; 20: 118-20.
13. BRUNN A, ZORNBACH K, HANS VH, HAUPT WF, DECKERT M: Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 2012; 71: 855-67.
14. AGGARWAL R, BANDOS A, REED AM et al.: Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014; 66: 740-9.
15. MILLER FW, RIDER LG, CHUNG YL et al.: Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 1262-73.
16. SULTAN SM, ALLEN E, ODDIS CV et al.: Reliability and validity of the Myositis Disease Activity Assessment Tool. Arthritis Rheum 2008; 58: 3593-9.
17. RIDER LG, KOZIOL D, GIANNINI EH et al.: Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62: 465-72.
18. LUNDBERG I, ULFGREN A, NYBERG P, ANDERSSON U, KLARESKOG L: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 1997; 40: 865-74.
19. ALEKSZA M, SZEGEDI A, ANTAL-SZALMáS P et al.: Altered cytokine expression of peripheral blood lymphocytes in polymyositis and dermatomyositis. Ann Rheum Dis 2005; 64: 1485-9.
20. BILGIC H, YTTERBERG S, AMIN S et al.: Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436-46.
21. SZODORAY P, ALEX P, KNOWLTON N et al.: Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members Bcell activating factor and a proliferation inducing ligand. Rheumatology (Oxford) 2010; 49: 1867-77.
22. BAUER J, BAECHLER E, PETRI M et al.: Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: e491.
23. FU Q, CHEN X, CUI H et al.: Association of elevated transcript levels of interferoninducible chemokines with disease activity and organ damage in systemic lupus erythematosus patients. Arthritis Res Ther 2008; 105: R112.
24. RODRIGUEZ-PLA A, PATEL P, MAECKER H et al.: IFN Priming Is Necessary but Not Sufficient To Turn on a Migratory Dendritic Cell Program in Lupus Monocytes. J Immunol 2014; 192: 5586-98.
25. PERNEGER T: What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236-8.
26. LUNDBERG I, BARBASSO S, ULFGREN A, GRACIE J, McINNES I: Expression of IL-18 in muscle tissue of patients with treatmentresistant idiopathic inflammatory myopathies. Arthritis Res Ther 2005; 7 (Suppl. 1): P57.
27. KURASAWA K, NAWATA Y, TAKABAYASHI K et al.: Activation of pulmonary T cells in corticosteroid-resistant and-sensitive interstitial pneumonitis in dermatomyositis/polymyositis. Clin Exp Immunol 2002; 129: 541-8.
28. LUND F, GARVY B, RANDALL T, HARRIS D: Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005; 8: 25-54.
29. SANZ I, ANOLIK J, LOONEY R: B cell depletion therapy in autoimmune diseases. Front Biosci 2007; 12: 2546-67.
30. PISTOIA V: Production of cytokines by human B cells in health and disease. Immunol Today 1997; 18: 343-50.
31. MIZOGUCHI A, MIZOGUCHI E, TAKEDATSU H, BLUMBERG R, BHAN A: Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002; 16: 219-30.
32. WOLF SD, DITTEL BN, HARDARDOTTIR F, JANEWAY CA Jr.: Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996; 184: 2271-8.
33. RATERMAN H, VOSSLAMBER S, de RIDDER S et al.: The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14: R95.
34. ROLL P, DöRNER T, TONY H: Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. AntiCD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-75.
35. REED A, CROWSON C, HEIN M et al.: Biomarker and Serologic Predictors Of Clinical Improvement After B Cell Depletion In Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)-The RIM (Rituximab in Myositis) Trial. [abstract]. Arthritis Rheum 2013; 65 (Suppl. 10): 2057.
36. BAECHLER E, BAUER J, SLATTERY C et al.: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13: 59-68.
37. GREENBERG S: Type 1 interferons and myositis. Arthritis Res Ther 2010; 12 (Suppl. 1): S4.
38. CHEN Y, SHI R, GERACI N, SHRESTHA S, GORDISH-DRESSMAN H, PACHMAN L: Duration of chronic inflammation alters gene expression in muscle from untreated girls with juvenile dermatomyositis. BMC Immunol 2008; 9: 43.
39. NIEWOLD T, KARIUKI S, MORGAN G, SHRESTHA S, PACHMAN LM: Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum 2009; 60: 1815-24.
40. De BLEECKER JL, de PAEPE B, VANWALLEGHEM IE, SCHRöDER JM: Differential expression of chemokines in inflammatory myopathies. Neurology 2002 Jun; 58: 1779-85.
41. WONG D, KEA B, PESICH R et al.: Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One 2012; 7: e29161.